What is Nexviazyme? Understanding a Targeted Treatment for Pompe Disease
•
5 min read
Affecting approximately 3,500 people in the US, Pompe disease is a rare genetic disorder treated by enzyme replacement therapies (ERTs). **What is Nexviazyme** and how does this second-generation treatment, developed by Sanofi, offer a new option for patients with the late-onset form of the disease?.
